Aspen Aerogels, Inc. filings document the company's aerogel technology business, operating results and material corporate events. Recent Forms 8-K cover quarterly and annual financial results, Regulation FD disclosures, business developments, manufacturing-facility updates, and amendments to the MidCap Loan Facility and related credit-party obligations.
The filing record also includes proxy materials describing governance, board and compensation matters, executive employment arrangements, equity awards and shareholder voting items. Aspen's disclosures connect its capital structure and credit covenants with operations in Energy Industrial and Thermal Barrier products, including PyroThin, Cryogel and Pyrogel applications.
Aspen Aerogels director Steven R. Mitchell received new equity awards as part of his non-employee director compensation. He was granted 10,370 Restricted Stock Units, each representing one share of common stock upon vesting. These RSUs vest on the earlier of May 13, 2027 or the day before the 2027 annual stockholders meeting.
Mitchell was also granted stock options for 8,706 shares of common stock at an exercise price of $5.40 per share, expiring on May 13, 2036. After these awards, he holds 156,898 common shares and RSUs in total, reflecting routine compensation-related acquisitions rather than open-market purchases.
Aspen Aerogels director James E. Sweetnam received new equity awards. He was granted 10,370 Restricted Stock Units as part of his annual compensation for service as a non-employee director. Each RSU converts into one share of common stock upon vesting in 2027.
He also received stock options for 8,706 shares of common stock at an exercise price of $5.40 per share, expiring on May 13, 2036. Following these awards, he holds 36,321 shares of common stock, including 10,370 RSUs.
Aspen Aerogels director William P. Noglows reported new equity awards and updated holdings. He received 10,370 Restricted Stock Units as part of his annual non-employee director grant, each RSU equal to one common share upon vesting. These RSUs vest on the earlier of May 13, 2027 or the day before the 2027 annual stockholder meeting. He was also granted stock options for 8,706 shares of common stock at an exercise price of $5.40 per share, expiring on May 13, 2036, with the same vesting schedule. After these grants, he directly holds 99,357 common-related units, consisting of 88,987 shares and 10,370 RSUs, and indirectly oversees 10,000 shares in each of two separate trusts for his children.
ASPEN AEROGELS INC director equity grant: Non-employee director Kathleen Kool received 10,370 Restricted Stock Units (RSUs) and options for 8,706 shares of Common Stock as part of her annual equity compensation. The RSUs and options will vest on the earlier of May 13, 2027 or the day before the company’s 2027 annual stockholders meeting. Following the RSU grant, she holds 34,323 shares of Common Stock in total, including 23,953 actual shares and 10,370 RSUs, and 8,706 stock options with a $5.40 exercise price expiring in 2036.
Aspen Aerogels director Cari Robinson reported equity awards for board service. On May 13, 2026, Robinson received 10,370 Restricted Stock Units (RSUs) and 8,706 stock options as part of the annual non-employee director equity grant.
Each RSU represents one share of common stock and will vest on the earlier of May 13, 2027, or the day before the company’s 2027 annual stockholders meeting. The options have a $5.40 exercise price, the same vesting schedule, and expire on May 13, 2036. Following these awards, Robinson’s reported position comprises 22,616 share equivalents, including 12,246 shares of common stock and 10,370 RSUs, held directly.
Aspen Aerogels reported a sharp revenue decline and a smaller loss for the quarter. Revenue for the three months ended March 31, 2026 fell to $37.9 million, down 52% from $78.7 million a year earlier, mainly from lower thermal barrier sales.
Net loss narrowed to $23.7 million (basic and diluted loss per share of $0.29) from $301.2 million ($3.67 per share), as the prior period included a large impairment related to the cancelled Statesboro plant. Aspen generated $34.1 million of cash from operations and ended the quarter with $173.9 million in cash and cash equivalents.
Deferred revenue rose to $36.6 million, helped by a $37.6 million customer settlement that is being recognized over about two years. After quarter-end, an explosion at the East Providence, Rhode Island plant halted operations; the company is relying on inventory, an external manufacturing facility and insurance while working to restart the site.
Aspen Aerogels reported a weak first quarter of 2026, with revenue falling to $37.9 million from $78.7 million a year earlier and an adjusted EBITDA loss of $12.7 million versus a $4.9 million profit. The thermal barrier segment dropped to $16.3 million from $48.9 million after regulatory and incentive changes reduced customer demand, while Energy Industrial revenue declined to $21.6 million from $29.8 million. Net loss narrowed to $23.7 million from $301.2 million, largely because the prior year included a large impairment charge; on an adjusted basis, net loss widened to $23.3 million from $4.8 million.
The company ended the quarter with $175.6 million in cash, cash equivalents, and restricted cash, helped by a $37.6 million commercial settlement payment from General Motors, of which $3.5 million was recognized as revenue and the rest deferred through 2027. Aspen’s East Providence, Rhode Island facility suffered an explosion on April 8, 2026, forcing a temporary shutdown; management expects a staged restart beginning in May while relying on inventory and an external manufacturing facility to support customers. For Q2 2026, Aspen projects revenue of $40–48 million, a net loss of $14–20 million, and adjusted EBITDA between negative $4 million and negative $10 million, and targets full-year 2026 capital expenditures of less than $10 million.
Aspen Aerogels reports that its East Providence, Rhode Island manufacturing facility remains offline following an explosion on the evening of April 8, 2026. The incident damaged part of the production area and forced a temporary halt to operations.
Preliminary reports point to a specific high-temperature oven as the source of the explosion. Eleven employees were transported to local medical facilities for evaluation and were later released. Aspen is working with relevant authorities on a plan to resume operations and has begun business interruption and property damage insurance claims. The company is still assessing the impact on its business and expects to provide a further update with its fiscal 2026 first quarter earnings release in early May.
Aspen Aerogels is holding its 2026 virtual annual stockholder meeting on May 13, 2026, asking investors to elect two directors, ratify KPMG as auditor, approve executive pay and its voting frequency, and support a future move to declassify the board. The board recommends voting for all proposals and choosing “One Year” for say-on-pay frequency.
The proxy also highlights 2025 actions to streamline operations, remove approximately $75 million of structural fixed costs, and strengthen the balance sheet. Aspen ended 2025 with about $159 million in cash and cash equivalents and expects nearly $38 million from a General Motors commercial settlement in Q1 2026, plus potential Plant II asset sales to further reduce debt.